Form 8-K - Current report:
SEC Accession No. 0000886163-24-000013
Filing Date
2024-04-19
Accepted
2024-04-19 16:06:41
Documents
14
Period of Report
2024-04-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20240417.htm   iXBRL 8-K 29699
2 EX-3.1 exhibit31fifthamendedandre.htm EX-3.1 162543
  Complete submission text file 0000886163-24-000013.txt   354913

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20240417.xsd EX-101.SCH 1911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20240417_lab.xml EX-101.LAB 22783
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20240417_pre.xml EX-101.PRE 13053
17 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20240417_htm.xml XML 2828
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 24857786
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)